Can the clinical outcome in state II colon carcinomas be predicted by determination of molecular marker expression?

Clinical and Translational Oncology

Volumn 9, Issue 10, 2007, Pages 663-670

  Fernandez Cebrian J M ^a   Nevado Santos, M ^b   Vorwald Kuborn, P ^a   Pardo de Lama, M ^a   Martin Cavanna J ^a   Pacheco Martinez P ^a   Fernandez Escudero B ^a   Ramos Fernandez M ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

Colorectal cancer; Molecular marker; Prognosis

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; CARCINOEMBRYONIC ANTIGEN; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER; BLOOD CLOTTING FACTOR 8;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER STAGING; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCUS; OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECURRENCE RISK; VASCULAR TUMOR; CARCINOMA; COLON TUMOR; MIDDLE AGED; MORTALITY; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; CARCINOMA; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FACTOR VIII; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 38449120824     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0119-z     Document Type: Article

References (34)

1. McKay JA, Douglas JJ, Ross VG et al (2000) Expression of cell cycle control proteins in primary colorectal tumor does not always predict expression in lymph node metastases. Clin Cancer Res 6:1113-1118
2. Allegra CJ, Paik S, Colangelo LH et al (2003) Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A national cancer institute-national surgical adjuvant breast and bowel project collaborative study. J Clin Oncol 21:241-250
3. Cascinu S, Staccioli MP, Gasparini G et al (2000) Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 6:2803-2807
4. Garrity M, Burgart L, Mahoney MR et al (2004) Prognostic value of proliferation, apoptosis, defective DNA mismatch repair and p53 overexpression in patients with resected Dukes'B2 or C Colon Cancer: A North Central Cancer Treatment Group Study. J Clin Oncol 22:1572-1582
5. Buyse M, Piedbois P (2001) Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 28:20-24
6. Galizia G, Orditura M, Romano C et al (2002) Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 102:169-178
7. Arber N, Hibshoosh H, Yasui W et al (1999) Abnormalities in the expression of cell cycle-related proteins in tumors of the small bowel. Cancer Epidemiol Biomarkers Prev 8:1101-1105
8. Fredersdorf S, Burns J, Milne AM et al (1997) High level expression of p27kip1 and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94: 6380-6385
9. Thomas GV, Szigeti K, Murphy M et al (1998) Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol 153:681-687
10. Palmqvist R, Stenling R, Oberg A, Landberg G (1999) Prognostic significance of p27Kip1 expression in colorectal cancer: A clinico-pathological characterization. J Pathol 188:18-23
11. Yao J, Eu KW, Seow-Choen F, Cheah PY (2000) Down-regulation of p27 is a significant predictor of poor overall survival and may facilitate metastasis in colorectal carcinomas. Int J Cancer 89:213-216
12. Hoos A, Nissan A, Stojadinovic A et al (2002) Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: A comprehensive analysis. Clin Cancer Res 8: 3841-3849
13. Polyak K, Xia Y, Zweier JL et al (1997) Model for p53-induced apoptosis. Nature (Lond) 389: 300-305
14. Vogelstein B, Fearon ER, Hamilton SR et al (1998) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525-532
15. Petersen S, Thames HD, Nieder C et al (2001) The results of colorectal cancer treatment by p53 status: Treatment-specific overview. Dis Colon Rectum 44:322-333
16. Grizzle WE, Manne U, Weiss HL et al (2002) Molecular staging of colorectal cancer in African-American and Caucasian patients using phenotypic expression of p53, Bc1-2, MUC-1, and p27(kip-1). Int J Cancer 97:403-409
17. Greene FI, Page DL, Fleming ID et al (eds) (2002) AJCC Cancer Staging Handbook. American Joint Committee on Cancer, 6th Edn. Springer-Verlag, New York
18. Duffy MJ, van Dalen A, Haglund C et al (2003) Clinical utility of biochemical markers in colorectal cancer: European group on tumour markers (EGTM) guidelines. Eur J Cancer 39:718-727
19. Oh-e H, Tanaka S, Kitadai Y et al (2001) Angiogenesis at the site of deepest penetration predicts lymph node metastasis of submucosal colorectal cancer. Dis Colon Rectum 44:1129-1136
20. Zhou W, Goodman SN, Galizia G et al (2002) Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet 359:219-225
21. Bazan V, Migliavacca M, Tubiolo C et al (2002) Have p53 gene mutations and protein expression a different biological significance in colorectal cancer? J Cell Physiol 191:237-246
22. Smith G, Carey FA, Beattie J et al (2002) Mutations in APC, Kirsten-ras, and p53 - alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A 99:9433-9438
23. Hoos A, Nissan A, Stojadinovic A et al (2002) Tissue microarray molecular profiling of early, node negative adenocarcinoma of the rectum: A comprehensive analysis. Clin Cancer Res 8:3841-3849
24. García-Sáenz JA, Sáenz MC, González L et al (2006) Significance of the immunohistochemical detection of lymph node micrometastases in stage II colorectal carcinoma. Clin Transl Oncol 8:676-680
25. Andre T, Sargent D, Tabernero J et al (2006) Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol 13:887-898
26. Cascinu S, Graziano F, Catalano V et al (2002) An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationship with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation. Br J Cancer 86:744-749
27. Kang S-M, Maeda K, Onoda N et al (1997) Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer 74:502-507
28. Barrier A, Boelle PY, Roser F et al (2006) Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 24:4685-4691
29. Le Voyer TE, Sigurdson ER, Hanlon AI et al (2003) Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 21:2912-2919
30. Kern A, Taubert H, Scheele J et al (2002) Association of p53 mutations, microvessel density and neoangiogenesis in pairs of colorectal cancers and corresponding liver metastases. Int J Oncol 21:243-249
31. Kawasaki H, Toyoda M, Shinohara H et al (2001) Expression of surviving correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer (Phila) 91:2026-2032
32. Yoshimura H, Chikamoto A, Honda T et al (2000) Relationship between microvessel quantification and inducibility of endogenous tumor necrosis factor in colorectal adenocarcinoma. Anticancer Res 20:629-634
33. Galizia G, Ferraraccio F, Lieto E et al (1999) DNA ploidy as a significant prognostic factor after radical resection for large bowel carcinoma: A prospective study. Oncol Rep 6:1013-1021
34. Jass JR, Ajioka JP, Chan YF et al (1996) Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopathology 28:543-548